Glaxo tipped for Danish drug deal

Geoff Foster
May 2013
Daily Mail;5/17/2013, p74
DRUGS giant GlaxoSmithKline, 10p easier at 1707.5p, was the focus of dealing room gossip, suggesting it could be lining up a knock-out cash offer of up to 300 kroner for Genmab after shares of the Danish drugsmaker soared 6pc to 180 kroner on turnover some 50pc above the daily average.


Related Articles

  • New drug (alosetron) approved for irritable bowel syndrome. Beyzarov, Elena Portyansky // Drug Topics;3/6/2000, Vol. 144 Issue 5, p33 

    Deals with Lotronex, an alosetron drug developed by Glaxo Wellcome for irritable bowel syndrome (IBS). Information on IBS; How serotonin, a neurotransmitter, activates alosetron; Results of the studies on alosetron; Major advantage of alosetron. INSET: Tips to Remember.

  • NeuroSearch Getting €32M from Janssen in Early Stage CNS Deal. Boggs, Jennifer // BioWorld Today;8/18/2009, Vol. 20 Issue 158, p1 

    The article reports that Danish biotechnology company NeuroSearch A/S in Ballerup, Denmark, has signed a deal with Janssen Pharmaceutica NV for the discovery of central nervous system drugs. It states that the three-year deal can be extended for another two years at Janssen's request, with...

  • Eltroxin: formulation change cause of ADR increase?  // Reactions Weekly;3/13/2010, Issue 1292, p2 

    The article unveils that the Danish Medicines Agency has been receiving various reports of suspected adverse drug reaction (ADR) with Eltroxin following the decision of GlaxoSmithKline to change the excipients contained in the medication.

  • GSK Picks a Side in MiR-122 IP Battle; Inks Regulus HCV Deal. Boggs, Jennifer // BioWorld Today;2/26/2010, Vol. 21 Issue 38, p1 

    The article reports that the pharmaceutical company GlaxoSmithKline plc (GSK) and biopharmaceutical company Regulus Therapeutics Inc. have partnered in a 150 million U.S. dollar venture to develop an miR-122 antagonist in hepatitis C virus. Prior to this deal, GSK declined an option for SPC3649,...

  • GSK fights US tax bill.  // Process Engineering;Jan2004, Vol. 85 Issue 1, p3 

    Reports that GlaxoSmithKline PLC intends to fight a multibillion dollar tax claim from the U.S. Internal Revenue Service (IRS) dating back to before the merger of SmithKline Beecham Corp. and Glaxo Wellcome PLC. Amount that the IRS claims the former Glaxo Wellcome owes in taxes for the years...

  • Raised cash deal sees GSK secure HGS. Ben Griffiths // Daily Mail;7/17/2012, p65 

    DRUGS giant GlaxoSmithKline sealed its purchase of US partner Human Genome Sciences yesterday with a sweetened, all-cash deal.

  • The premium of a big pharma license deal. O'Connell, Kara E; Frei, Patrik; Dev, Kumlesh K // Nature Biotechnology;Jul2014, Vol. 32 Issue 7, p617 

    A letter to the editor is presented related to the drug license deal of several pharmaceutical companies including Novartis, GlaxoSmithKline and Pfizer.

  • New protease inhibitor offers favorable resistance pattern. Portyansky, Elena // Drug Topics;5/17/99, Vol. 143 Issue 9, p28 

    Focuses on Agenerase, a protease inhibitor from Glaxo Wellcome. Results of the two studies conducted on the drug; Benefits of amprenavir; Side-effects of the drug. INSET: Tips to Remember.

  • Sole strength. Gopal, Kevin // Pharmaceutical Executive;May98, Vol. 18 Issue 5, p30 

    Highlights the failed merger of SmithKline Beecham (SB) with Glaxo Wellcome (GW). Description of drugs and vaccines of SB; Comments on the failed deal; List of drugs in clinical trials; Progress in discovery technologies of SB.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics